Nika Pharmaceuticals Inc. Stock Analysis NIKA

Nika Pharmaceuticals, Inc. engages in the development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. The company is headquartered in Henderson, Nevada and currently employs 0 full-time employees. The company went IPO on 2024-01-24. The company has the exclusive rights agreement for the production and distribution of two dietary supplements, namely Carotilen and Physiolong. Carotilen is a dietary supplement in the form of soft gelatin capsules that improves and regulates the metabolism of the epithelial cells and protects them from degenerative alterations. Physiolong is a dietary food supplement in the form of hard gelatin capsules, which serves as a general stimulant for those in a period of convalescence, as well as in situations of high mental and physical loads. The company has an exclusive rights agreement for the production and distribution of Thymus Nuclear Glycoprotein (TNG). The company also has the rights agreement for the production and sale of an additional six dietary supplements, such as Hypocholestin, Biodetoxin, Dry Boza, Fructin, Anthocylen C, and Silymaron.